|TOPCAT: Treatment of diastolic heart failure with medication|
|Treatment of Preserved Cardiac Function Heart Failure with Aldosterone-antagonist (Amended Protocol, Version 1.7, June 04, 2009)|
|Thomas Cappola, MD,ScM|
Why is this study being done?
|This study is being conducted to see if adding a drug called spironolactone will help patients with diastolic heart failure. |
Who is eligible to participate in this study?
|To be elibible for this study, subjects need to have heart failure with an ejection fraction greater than or equal to 45% as measured by an echocardiogram.
What is involved with this study?
|Subjects will be randomized to either the study drug or placebo. Subjects will be expected to attend office visits. Follow-up safety labs will be drawn at each office visit. |
How long will this study run?
|This is a large NIH funded study and the duration for participation will be 4.5 years. Planned office visits will occur every four months during the first year and every six months thereafter. |
Who can I contact for additional information on this trial?
|Judy Marble, RN, MS